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ABSTRAK 
Pengenalan: Kepelbagaian respons pesakit glaukoma terhadap ubat titis mata Iatanoprost 
bukannya isu yang baru, kebanyakan penyelidik berpendapat ia melibatkan faktor kaum, rejim 
rawatan dan mungkin juga akibat polimorfisma gen. 
Objektif: Kajian ini bertujuan mengenalpasti kewujudan polimorfisma gen pada PTGFR dan 
peranannya ke atas keberkesanan ubat titis mata latanoprost di kalangan pesakit glaukoma. 
Metodologi: Pesakit-pesakit glaukoma yang dirawat dengan ubat titis mata latanoprost 
diperiksa dan disusuli selama 6 bulan. Corak tekanan mata dikaji dan perbezaan respons pesakit 
dikenalpasti. Polimorfisma gen pada bahagian ekson gen PTGFR dikenalpasti di ka1angan 
pesakit dan juga kontrol dengan menggunakan kaedah 'dHPLC' (denaturing high performance 
lipid chromatography). Polimorfisma yang ditemui itu akan dikaitkan dengan corak penurunan 
tekanan mata dan perbezaan respons pesakit. 
Keputusan: Seramai 76 pesakit g1aukoma dan kontrol te1ah disaring dan tiada variasi ekson 
yang ditemui. Walaubagaimanapun, satu polimorfisma nukleotida tunggal (SNP) baru pada 
intron telah ditemui pada kawasan 5'flanking ekson-3 di ka1angan 46% daripada pesakit dan 
kontrol. Min penurunan tekanan mata adalah 33.1% pada bulan ke 6. Se1epas 3 bulan rawatan 
dengan ubat titis mata latanoprost, sebanyak 47.4% pesakit glaukoma mencapai penurunan 
tekanan mata cecah 30% atau lebih (pesakit respons baik), 28.9% mencapai penurunan tekanan 
mata antara 15% hingga 30o/o (pesakit respons sederhana) dan 23.7% pasakit mencapai 
penurunan tekanan mata kurang daripada 15% (pesakit respons kurang). SNP lntron ini 
didapati tidak berkaitan dengan pesakit glaukoma, kaum dan keberkesanan ubat titis mata 
latanoprost. 
Kesimpulan: Ubat titis mata latanoprost adalah berkesan di kalangan pesakit glaukoma 
tempatan. SNP intron pada gen PTGFR yang baru dijumpai ini tidak berkaitan dengan penyakit 
glaukoma dan keberkesanan ubat titis mata latanoprost. 
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ABSTRACT 
Introduction: Diversity in clinical response among glaucomatous patients in response to 
topical latanoprost is not a new issue, many researchers attributing it to the different races, 
treatment regimes, glaucoma types, and some genetic variants. 
Objective: The objective of this study is to determine the presence of polymorphism in 
exon of PTGFR gene and its role in responsiveness of glaucoma patients to topical 
latanoprost treatment. 
Methodology: Glaucoma patients started on topical latanoprost were followed up for 6 
months. Pattern of lOP and rate of good responder (30% reduction or more), moderate 
responder (15-30% reduction) and poor responder (less than 15% reduction) were 
determined. Polymorphism of the PTGFR protein coding region was identified among the 
glaucoma patients and the controls using denaturing High Performance Chromatography 
( dHPLC). The identified polymorphisms were associated with glaucoma and the pressure-
lowering effect of topicallatanoprost among glaucomatous patients on treatment. 
Result: From 76 glaucoma patients and controls screened, no exon SNP was found. One 
novel intron nSNP<A-T) at 5'flanking region of exon-3 with frequency of 46% was 
identified. Among the glaucoma patients, mean lOP reduction was 33.1% and there was as 
high as 47.4% good responder, 28.9% of moderate responder and 23.7% of poor responder. 
The lntron SNP was statistically found to be neither associated with the responder rate, the 
race nor with glaucoma patients. 
Conclusion: Topical latanoprost is effective among glaucoma patient in our local set up. 
The novel intron SNP found within the PTGFR gene does not statistically associate with 
glaucoma and clinical lOP lowering effect among glaucoma patients receiving topical 
latanoprost. 
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Chapter 1 
Introduction 
INTRODUCTION 
1.1 BACKGROUND 
Since the introduction of the latanoprost, the prototype of prostaglandin analogue in 
1996, various clinical trials has concluded the effectiveness, side effects, possible 
complications, tolerability and also incidence of poor or non-responder. 
Averages of 28 to 31 % of intraocular pressure {lOP) reduction by latanoprost 
monotherapy treatment were concluded in various clinical researches (Van der Valk et 
al, Zhang et al, 2005). The response to the latanoprost in various reviews was found to 
be less predictable and varies in subpopulations. For example in cases of non or poor 
responders to latanoprost, various studies had recorded figure at 10-20% but some 
studies recorded up to 50% of poor or non responder (Susanna and Medeiros, 2001; 
Hedman et al, 2002). A study comparing the effectiveness of the lOP reduction also 
found that Asian and Mexican glaucoma patients may be responding better to 
latanoprost over timolol than the corresponding population in the Caucasian (Hedman 
& Larsson , 2002). 
Along with the reports of diversity in lOP lowering effects, it is observed that side 
effects were also varies in subpopulations; iris hyperpigmentation was only observed 
among Caucasian but hypertrichiosis, conjunctival hyperemia, was universal. 
Moreover, hyperchromic irises were found only in specific iris colored patients (Aim et 
al, 1994) 
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Wadhwa & Higginbotham (2005) in a revtew raised an issue of whether these 
phenomenons can be explained by the distribution of the single nucleotide 
polymorphism (SNP) within the gene rather than ethnicity. 
And thanks to recent advances in molecular genetic and genome sequencing 
techniques, pharmacogenetic researches in identifying genes and allelic variants of 
genes that affect our response to current drugs has gained enormous momentum (Wolf 
et al, 1997). With growing awareness of the pharmacogenetic studies and contemporary 
knowledge in efficient laboratory techniques, clinical observed response discrepancies 
found within populations or subpopulations were extensively under investigation with 
the vision of tailoring the therapies to individuals in the future. 
Clinical trials on latanoprost published were mostly conducted in the western 
population but hardly any in our populations. Evidence and information regarding 
extend of effectiveness and validity of the labeled side effects of the drug is still vague 
in local set up. This dissertation was designed to study primarily the lOP lowering 
effects of latanoprost in the local glaucoma patients and its association with genetic 
polymorphism of the prostanoid (FP) receptor. 
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1.2 PHARMACOGENETIC 
Pharmacogenetic refers to inborn variation in any group of creatures in response to 
xenobiotics (biologically active material formed outside host's body e.g. drug) (Kalow, 
1997). Recently, pharmacogenetic research has gained tremendous momentum with the 
advances in molecular genetic and genome sequencing. The two main direction of 
pharmacogenetic studies were actually either identification of specific genes and gene 
products associated with various diseases (which may act as targets for new drugs) or 
identifying genes and allelic variants (such as SNP) of genes that affect our response to 
current drugs (Wolf et al, 2000). 
Diversity of clinical response in various population and subpopulation had cited many 
researchers to correlate the phenomenon to racial differences. But with the fact that 
world population shares 99.9% of its genes and greater diversity in fact were found 
within the population instead of between them, study of polymorphism such as SNP 
distribution and its functional correlation would probably more relevant (Wadhawa & 
Higginbotham, 2005). Researchers were currently investigating genetic polymorphism 
that may be of therapeutical or toxicological importance with regards to clinical 
response of patients toward the prescribed medications. 
3 
1.3 RECEPTOR AND GENETIC POL YMORPHISMS 
Polymorphisms were identified in more than 20 human drug metabolizing enzymes 
several with substantial race differences in their frequencies in year 2000. Some of 
them were critical determinants of therapeutic outcome (Wolf et al, 2000). One of the 
most studied enzymes would be the debrisoquine hydroxylase and its Cytochrome P450 
coding CYP2D6 gene. Polymorphism of CYP2D6 gene is exhibited by the poor 
oxidation of debrisoquine (which is a sympatholytic antihypertensive agent) and is 
inherited as an autosomal recessive trait (CYP2D6 gene) in up to 10% of the British, 
German and Finnish population (Greenlee & Kwon, 2003). Cytochrome P450 CYP2D6 
gene controls expression of the debrisoquine hydroxylase expression causes the diverse 
response to various psychiatric, cardiovascular and neurological drugs including beta-
blocker such as timolol. Polymorphism of enzyme thiopurine methyltranferase which is 
responsible for the metabolism of the anti-tumour agents 6-mercaptopurine and 6 
thioguanine is another example (Kalow, 1997). 
Apart from enzymes polymorphism, receptor polymorphism and corresponding gene 
polymorphism is another identified potential determinant of therapeutic outcome that 
have been investigated in pharmacogenetic studies. For example, the ~-receptor 
polymorphisms as consequences of mutagenesis had proven to alter the adrenergic 
receptor function. Typically the genetic polymorphisms influence the receptor 
expression, agonist and antagonist-binding affinities, physical and functional coupling 
to stimulatory G protein (Gs), receptor trafficking and receptor regulation by agonist 
(Liggett et al, 2000) (Table 1.1 ). Most of these receptor polymorphisms were resultants 
of the single nucleotide polymorphism (SNP). 
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Table 1.1: P-Receptor polymorphism and the phenotyping 
Nucleic acid Amino acid no Designation Phenotype 
46 16 Arg-16 Reference 
Gly-16 Enhanced downregulation 
79 27 Gln-27 Reference 
Glu-27 Absence downregulation 
100 34 Val-34 Reference 
Met-34 Normal 
491 164 Thr-164 Reference 
Ile-164 Decrease coupling, binding & sequestration 
-47 19 5'LC Arg Reference 
5'LC Cys Increased expression 
1.4 SINGLE NUCLEOTIDE POLYMORPHISM (SNP) 
SNP were Deoxyribonucleic acid (DNA) sequence variation, occurring when a single 
nucleotide containing base such as adenine (A), thymine {T), cytosine (C) or guanine 
(G) in the genome is altered to another base. A variation must occur in at least 1-2% of 
the population to be considered polymorphism. In the late 90, there was an increase in 
interest towards SNPs among molecular geneticists because they were believed to be 
associated with the commoner complex familial disorders like diabetes, osteoporosis, 
cardiovascular or cancerous diseases. Potential merit of SNP as a marker for various 
diseases became the mission in many genome projects (Gray et al, 2000). Parallel to it, 
there is also growing of enthusiasm in association of genetic of drug response relating 
to SNP (Pharmacogenetic study). 
SNP was estimated to cover the human genome at an average spacing of 1 SNP per 
2000bp. In 2002, Haga et al (2002) resequenced 24 Japanese individuals and from 5% 
of the human genome analysed, they estimated frequency of SNP in the Japanese 
5 
population to be as frequent as one SNP in 807 bp. They have identified 174,269 SNP 
and 16,293 insertion/deletion polymorphisms within the screened gene region. 
Although the presence of SNP can affect how humans handle diseases, bacteria, 
viruses, chemicals, drugs, etc., most of them do not. Miller & K wok in their review on 
United State population had indicated that there are as many as --17% of the candidates 
SNPs in the collection of databases had no detectable variation in any of the 3 major 
populations in the US (African-Americans, Asian, and Caucasians) and would not be 
useful for genetic studies. 
About 6% of all SNPs are rare alleles which are always less than 20% in any 
population; --53% are common SNPs that were 20% or more in any one population. 
Only --27% of the SNPs candidates are common in all three populations (Miller and 
K wok, 2001 ). Another aspect in pharmacogenetic is the study of Linkage 
disequilibrium (LD) among the potential SNPs. It is a measure of the degree of 
association between alleles in a population. The detection of disease-causing variants 
by association with neighboring single nucleotide polymorphisms (SNPs) depends on 
the existence of strong LD between them. LD could be disease linked or ethnic linked. 
Mukhopadhyay et al (2002) in a study on Indian patients discovered a total linkage 
disequilibrium of 2 SNP (- 83°-A and 227°-A) within the myocilin gene among the 
Asian population but weak linkage among the Caucasians. 
In Ophthalmology, SNP found within the specific loci in the chromosome 1, 2, 3, 7, 8, 
1 0, had been associated with risk of glaucoma. Apart from the well recognized 
6 
Myocilin (MYOC) and Optineurin gene, SNP on intervening sequence 8 of the OPAl 
gene had been also recently found to be strongly associated with normal tension 
glaucoma but not higher pressure primary open angle glaucoma (Aung et al, 2001). 
1.5 GLAUCOMA 
1.5.1 DEFINITION AND PREVALENCE 
Glaucoma represents a group of diseases with characteristic optic neuropathy and 
associated visual field loss for which elevated intraocular pressure (lOP) is one of the 
primary risk factors (AAO, section 10; 2000-2001). It is traditionally classified as 
primary (open or closed angle) glaucoma and secondary (open or closed angle) 
glaucoma. Primary open angle glaucoma (POAG) with normal or low intraocular 
pressure is known as normal tension glaucoma (NTG) or normal pressure glaucoma 
(NPG). 
Glaucoma, especially POAG is a relatively low disability /case ratio disease which 
surface only in the past few decade as a major threat of blindness in Ophthalmology. 
Based on 111 published data, Harry Quigley estimated by 2000, the number of people 
with primary glaucoma to be at 66.8million and nearly 10% of them would suffer from 
bilateral blindness (Quigley, 1996). Even back in late 1980-early 1990, World Health 
Organization's (WHO) had estimated the incidence of primary open angle glaucoma 
(POAG) per year to be 2.4 million and the prevalence of POAG is between 1.1 to 2.1% 
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in general. It has been recognized as the second leading causes of blindness in the 
world now (Quigley, 1996). 
Epidemiological studies in neighboring countries like Thailand found glaucoma as the 
second most common cause of unilateral blindness after cataract and in the study, it 
accounted for 11.2% of blindness (Bourne et al, 2003). In Singapore, Tanjong Pagar 
study found glaucoma was the largest contributory cause of blindness in population 
aged more than 40 year old (60%) followed by cataract and age related macular 
degeneration (Saw et al, 2004). Malaysian National Eye Survey, a population based 
study in 1996 estimated glaucoma to be merely the 5th major cause of bilateral 
blindness ( 1. 77% ). But because the definition of glaucoma was far from satisfactory, 
the figure was generally agreed to be underestimated (Zainal et al, 2002). 
Glaucoma patients generally present late especially the POAG and NTG. Late 
presentation had been shown to be the major contributory factors of blindness (29-41%) 
(Chen, 2004). Poor awareness of the disease would be another issue in the high 
prevalence of blindness in glaucoma. In a review, Hugh Taylor reported more than half 
of those in developing countries with glaucoma are actually unaware of the disease 
(Taylor & Keeffe, 2001) and even in developed countries, 75-78%> of population had 
heard of glaucoma but only fewer than 1 0 % could actually identified a basic glaucoma 
definition correctly (Pfeiffer et al, 2002; Lau et al, 2002). In a recent cross-sectional 
study in our glaucoma population in Penang, Malaysia, Chi eng et al found 8.1% of 
glaucoma patients were blind bilaterally and 14.9% had low vision at time of diagnosis. 
Almost one third of the diagnosed patients had demonstrated severe disc cupping of at 
8 
least 0.8 on presentation but 60.5% of them were still possessing satisfactory good 
vision of more than 6/18 or better at least in one eye (Chi eng et al, 2005). 
1.5.2 RACIAL DIFFERENCE IN GLAUCOMA 
In general, the black race were not only found to have a higher prevalence of glaucoma, 
they also have younger presentation of the disease by 5-10 years, higher initial lOP, 
more severe course of disease and also postulated to have different efficacy of therapy 
due to heavier pigmentation of the eye (Wadhwa and Higginbotham, 2005; Grehn, 
2001 ). They also scar more readily leading to poor success rate of glaucoma filtration 
surgery. Conversely, blacks were found to respond better to travaprost treatment by up 
to 2.4mmHg, although not with latanoprost and timolol treatment (Netland et al, 2001). 
Hedman and Larson (2002) in a pooled 8 clinical trials analysis found Asian and 
Mexican patients showed a larger difference in mean diurnal lOP reduction between the 
timolol and latanoprost treatment as compare to patients from Europe and the United 
States. Greenlee and K wan (2002) had emphasized the existence of different responses 
of treatment in various races and the necessity for clinicians to adjust the expectation of 
efficacy and side effect accordingly. Evidence was not strong enough to conclude the 
relationship between races and the drug responses in glaucoma management due to 
complex confounding factors such as socioeconomic and educational background. 
Along with that, the differences that exist between races ultimately are still largely 
dictated by the genetic basis. Thus the genetic polymorphism would probably be the 
important factor rather than race in etiology of glaucoma and the response to drug 
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treatment in glaucoma patients. At least 2 trials had found the myocilin mutation 
incidence between the African American and the whites were almost equal (Wadhwa & 
Higginbotham, 2005) indicating the implication of genetic mutations in the aetiology of 
glaucoma. 
1.5.3 MANAGEMENT OF GLAUCOMA 
Glaucoma was once described by Fred Hollows as a disease which we do not know 
how to treat. It is a group of pathological entities with different pathophysiological 
mechanisms of action, characterized by ocular damage related in part to lOP. Recent 
researches have concluded pressure independent mechanism such as vascular and 
structural alteration of the optic nerve head may contribute in some cases to 
glaucomatous damage to the optic nerve (Tarek & Spaeth, The Glaucomas-concept and 
fundamental, 2000). 
For centuries, the aim of management in glaucoma is mainly treating the obvious 
feature, which is the elevated lOP. Clinical evidence in effectiveness of treatment of 
glaucoma was vague (Wilensky, 1999) until Millennium when benefit of lowering lOP 
came to light, evidenced by various large clinical trials (Collaborative normal tension 
glaucoma study group, 1998; Heijl et al, 2002; The AGIS Investigators, 2000; The 
ocular hypertension treatment study, 2002). Current evidence does not find any lower 
limit ofbenefit of lOP lowering (Heijl et al, 2002; The AGIS Investigators, 2000). 
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The general principle in glaucoma management now is to maintain the patients' quality 
of life and quality of vision at a sustainable cost apart from control the lOP lower than 
target pressure. Target pressure is defined as the mean of an estimate lOP with 
treatment that is expected to prevent further glaucomatous damage (Tarek & Spaeth, 
The Glaucomas-concept and fundamental, 2000; European Glaucoma society, 2003). 
The initial target pressure is at least 30% lower than the initial lOP. This (30% 
reduction) has shown to reduce the rate of visual field progression from 35% to only 
12% (Collaborative Normal Tension Glaucoma Study Group, 1998). The exact level of 
target lOP cannot be predicted with complete accuracy and lOP below 15 mmHg seen 
to be satisfactory in most but not all cases (Tarek & Spaeth, The Glaucomas-concept 
and fundamental, 2000). 
Reducing lOP can be done via various options including topical or oral medications or 
engaging in surgical procedures like filtering surgery, trabeculotomy, or even laser 
therapy. Nevertheless, the main stay of treatment in POAG, NTG and OH currently is 
still the topical ocular hypotensive agents unless indicated (as in secondary glaucoma 
where relief of the primary cause would be the ultimate treatment or when topical anti-
glaucoma is unlikely to provide effective lOP control). 
Choices of ocular hypotensive agents were once limited, but now there are at least 5 
different classes of anti-glaucoma agents to choose from which include beta blocker 
(e.g. timoptol, betaxolol etc), parasympathetic agonist (pilocarpine), carbonic 
anhydrase inhibitor (e.g. dorzolamide and brinzolamide ), adrenergic agonists (e.g. 
propine, adrenaline) and alpha 2 agonist (brimonidine ). Most are associated with major 
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side effects. Prostaglandin analogues like latanoprost, travaprost and bimatoprost are 
another newly discovered class of ocular hypotensive agents. They are certainly the 
most indispensable and inarguably the most effective ocular hypotensive agent 
available in the market now (Van Der Valk et al, 2005). 
1.6 LATANOPROST 
1.6.1 BACKGROUND 
Since the introduction of latanoprost (first commercially available prostaglandin 
analogue) in 1996, prostaglandin analogues have become the most prescribed anti-
glaucoma therapeutic agent. They were found to be the most effective ocular 
hypotensive agent in treatment of primary open angle glaucoma (Van der Valk et al, 
2005). Other prostaglandin analogues available in the market are travaprost (Travatan 
0.004%, Alcon) and Bimatoprost (Lumigan 0.03%, Allergan), which are both isopropyl 
ester and amide prodrugs respectively. 
Topical Latanoprost 0.005% (Xalatan, Pfizer), is a synthetic prostanoid selective FP 
receptor agonist (isopropyl - (Z)-7 [ (1R,2R,3R,5S ) 3, 5 -dihydroxy- 2 - [(3R) - 3 -
hydroxyl- 5 - phenylpentyl]cyclopentyl]- 5 - heptenoate with molecular formula of 
C26 H40 Os). It is a prodrug with two long carbon chains (alpha and omega). The alpha 
chain is associated with easy penetration through the cornea where it is metabolized by 
an esterase enzyme in cornea to become latanoprost free acid ( Ph XA 85). The omega 
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chain is responsible for the potency and selective FP receptor activation in the anterior 
chamber (Hylton & Robin, 2003). 
It is well known that prostaglandin analogues reduce IOP via increased non-
conventional uveoscleral outflow but the exact mechanism is still unknown. 
Researchers had found that in conjunction with the FP receptor binding, prostaglandin 
analogues interacts with the nucleus resulting in transcription of genes that biosynthesis 
pro-MMPs (matrix metalloprotease) which activates the MMPs (a group of collagenase 
important in remodeling of the collagen tissue). MMPs break down the collagen in the 
extracellular matrix and are being washed out with the aqueous as it flow through the 
uveoscleral pathway, thus opens up the pathway. Weinreb found exposure to 
prostaglandin F2a, 17-phenyltrinor-PGF2a, or latanoprost acid increased scleral 
permeability by up to 124%, 183%, or 213%, respectively; and MMPs were increased 
by up to 37%, 267%, and 96%, respectively. Transscleral absorption ofFGF-2 was also 
increased by up to 126% with scleral exposure to latanoprost (Weinreb, 2001 ). This 
still does not explain the immediate lOP lowering effect seen within hours of 
administration (Hylton & Robin, 2003). Some researcher attributed it to the early 
relaxation of the ciliary muscle but is still unproven. 
There is also evidence that latanoprost may influence cyclo-oxygenase and nitric oxide 
synthase activities and interfering with ischemia-induced neurotoxic processes and 
conferring neuroprotective postulation of the drug. In animal studies, significant 
increase in optic nerve head blood velocity has been found in rabbit and monkey eyes 
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after treatment with the latanoprost probably by relaxing the ciliary artery (Hylton & 
Robin, 2003 ). 
1.6.2 INTRAOCULAR PRESSURE-LOWERING EFFECT 
Latanoprost has been proven a well tolerable drug with effective lOP reduction of 28-
31% (when used as Monotherapy) in POAG and Ocular hypertension patients, as 
shown in various control trial across various countries and races (Aim and Widengard, 
2000; Liu et al, 1999; O'Donoghue et al, 2000; Aung et al, 2001; Hedman & Larsson, 
2002; Tsukamoto et al, 2002; Kontas et al, 2003; Vander Valk et al, 2004; Thomas et 
al, 2005). 
When topical latanoprost was used as adjunctive therapy to other class of ocular 
hypotensive agents, it was also found to be as effective. Addition of latanoprost (which 
enhances ourtlow facility), to various aqueous suppressants such as timolol and 
carbonic anhydrase inhibitors, would logically produce a pure additive effect. Clinical 
trials have reported excellent additive effect of topicallatanoprost as adjunctive therapy 
to various drugs with further lOP reduction of 23.2% to 26.1% irrespective of drugs 
used prior to the initiation of latanoprost (Bayer et al, 2002; Hoyng et al 1997). 
With concern on the additive effect of latanoprost treatment in patients not controlled 
with topical timolol, the lOP reductions were found to be less consistent. Rulo et al 
(1994) reported that only a 13% further reduction was recorded at 2 weeks; conversely 
about 32% (4weeks) and 37% (12weeks) reduction was reported by Aim et al (1995). 
Hoyng et al ( 1997) in their study reported a large range of further reduction from 13% 
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to as high as 37%. Bron et al (2001) found further reduction of the lOP in the order of 
25% by latanoprost at 2 and 6 week in patients adequately controlled with timolol alone 
or in combination with some other drug. 
Recent clinical data also shows inconsistent findings with adjunctive latanoprost on 
timolol. It has been shown to produce an excellent further lOP reduction of 23.5% at 
1month (Simmon et al, 2001) and 24.03% at 6 months (Diestelhorst et al, 2000); but 
Higginbotham et al (2002) reported only 10.65% reduction at 6 months of treatment. 
Nevertheless, should the baseline lOPs of the various studies be taken into 
consideration, we find the lOP reduction were rather consistent at 20-30%. With 
average baseline lOP of 20-25mmHg, lOP lowering effect among latanoprost 
adjunctive therapy was slightly lower than effect of reduction by monotherapy with 
magnitude of --5%. 
Pathophysiologically, the mechanism of action of beta-blockers are believed to via 
beta-adrenoceptor mediated modulation of the intracellular cyclic-Adenosine 
monophosphate (cAMP) concentration in the ciliary epithelium, which affects the active 
transport capacity of cliliary epithelium, thus reducing aqueous production by as much 
as 50% (Hoyng et al, 1997). Adding of latanoprost to timolol would obviously induce 
pure additive effect although it does not proportionately shown, clinically. 
Lately, small proportion of patients have been found to be non responsive to topical 
latanoprost and labeled as non responder. Although the definitions may differ slightly 
but generally non-responder rate of latanoprost in various subpopulation were estimated 
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from I 0% to as high as 51.5%. Scherer (2002) found 25% of non responder (reduction 
less than 20% of baseline or less than 5mmHg reduction) in a retrospective review of 
20 patients. Up to 13.5% non-responders (less than 3mmHg at 20 hour after dose) had 
been documented by Netland et al (2001). In another study, 18-35% of latanoprost 
treated patients achieve less than 15% lOP reduction (Noecker et al, 2003). Choplin et 
al (2004) in 136 patients on Iatanoprost treatment found extremely high non responders 
rate ranging from 39.2%-51.5% (definition of <15% reduction). In Singapore, Aung et 
al (2001) have found only 11.3% to 14.8% of patients respond less than 15%. 
Similarly, there has been different proportion with exceptionally good pressure 
lowering effects of responders (Camras and Hedman, 2003). Much needs to be answer 
as to what are the factors dictating this diversity of response. Attributing factors could 
well be racial difference, iris color difference, compliance or mere statistical error. 
Subpopulation genetic differences such as SNP are under research for various 
pharmacogenetic studies and we postulated that the diversity of response to latanoprost 
could be due to the diverse mutations within the population related to SNP. 
1.6.3 SIDE EFFECTS 
As with all other prostaglandin analogues, clinical efficacy of latanoprost comes at the 
expense of side effects. They are mainly conjunctival hyperemia 27.6% and foreign 
body sensation, prostaglandin induced iris pigmentation 5-15% (PIIP), hypertrichiosis 
5.2%, possible breakdown of ocular blood barrier and cystoid macula oedema (Netland 
et al, 2001 ). 
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Clinical trials compared side effects among the prostaglandin analogues found the 
conjunctival hyperemia was least in latanoprost (Stewart et al, 2003). This is believed 
to be due to higher specificity of the drug to FP receptors and weaker agonist activity of 
latanoprost on the EP2, IP and TP receptor which are known to mediate the vascular 
effects (Stjernschantz et al, 2000; Hoyng et al, 1997). Esterification of carboxylic acid 
group of the relatively hydrophilic latanoprost (prodrug) enhanced the corneal 
penetration and the activation of the prodrug by the esterase only occurs within the 
corneal. Apart from reducing the amount of drug required, it minimize the 
concentration of active compound at the surface, thus reduce the conjunctival 
hyperemia.(Hoyng et al, 1997). 
PIIP and periocular skin pigmentation appears to be more prevalent in patients taking 
latanoprost (Hylton & Robin, 2003). However, none of the 60 Asian patients displayed 
PIIP after 2 months of exposure to latanoprost and unoprostone as reported by Aung et 
al (2001). Conversely, PIIP was a major concern in Caucasian, because of the lighter 
iris color in the population (Zhang et al, 2005). 
There should be caution when prescribing latanoprost in high-risk patients with 
pseudophakic and aphakic eyes, as prostaglandin analogues were known to accelerate 
the disruption of the blood aqueous barrier and increase the incidence of cystoid macula 
oedema (Miyake & Nobuhiro, 1999). 
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Aung et al (200 1) found that latanoprost is well tolerated in Asian patients with few 
ocular adverse events. About a third (32.43%) of their patients developed ocular 
irritation, 35% developed conjunctival redness, 2. 7% developed skin rash and another 
2. 7% developed transient anterior chamber cells but none of the latanoprost patients 
stopped therapy due to side effects. 
1.7 PROSTANOID (FP) RECEPTOR AND GENE 
CliO CHO 
Figure 1.1: Showing the 7 putative transmembranous domains in the prostanoid 
receptor (A) and the G protein coupled activation of IP3 (lnophosphate 3) (B) 
(Adapted from Narumiya et al, 1999) 
1.7.1 PROSTANOID (FP) RECEPTOR: 
Prostanoid receptors are the membrane receptors mediating the actions of the 
prostanoids. They are G protein-coupled receptors with 7 putative transmembraneous 
domains (Figure I. I A). Prostanoids are locally acting autocrine or paracrine molecules 
with wide spectrum of biological activities. One receptor has been identified 
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pharmacologically for each natural occurring prostanoids depends on the individual 
affinity. Identified prostanoids include Prostaglandin (PG) D2, PGF2a, prostacyclin 
(PGh) and thromboxane A2 which has individual affinity towards their corresponding 
receptor named the DP-, FP-, IP- and TP receptors (-Rs). Four prostanoid receptor 
subtypes have been characterized pharmacologically for PGE2, named EPl-R to EP4-R. 
Selective agonist for virtually all prostanoids affect lOP, but among all PGF2a was 
identified in 1980s as the most effective ocular hypotensive agent. FP receptor 
inevitably became the receptor of interest among the researchers. Nevertheless, the 
underlying physiological mechanisms of lOP lowering are only partially understood. 
The human FP receptor consists of 359 amino acid residues with a predicted molecular 
mass of 40,060. Activation of FP receptor leads to Gq mediated inositol phosphate 3 
(IP3) generation and subsequent increase in intracellular calcium (Figure l.lB). FP 
receptor also coupled to other signal transduction systems (G-protein Rho mediated, 
phospholipid-C-~ mediated etc). 
Even though prostaglandins in general were well recognized as the important mediators 
of inflammation, there is little evidence to support FP receptors' role in inflammatory 
and immunological processes signaling (Hata & Breyer, 2004). 
Expression of FP receptors is found in the corpus luteum of ovaries, myometrium 
which is linked to prolonged, painful menstrual bleeding and endometrial 
adenocarcinoma growth; in heart, they are associated with myocytes hypertrophy; in 
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stomach, FP receptor is linked to the protection of mucosa thus gastric ulcer; and in 
eye, it is associated with regulation of lOP. FP receptors are also found in the liver, 
respiratory tract and the kidney. 
In the eye, only modest FP receptor is found in the ciliary muscle and virtually 
undetectable in NPE cells. Low level of mRNA was detected in corneal epithelium, 
ciliary processes, iris, inner retina, optic nerve and lens epithelial cells (Woodward et 
al, 1997). Introduction of PGF2a and their analogs have been shown to lower intraocular 
pressure in humans which is believed to be mediated by the FP receptor. 
Apart from that, melanocytes in eye were also found to express FP receptors. They 
stimulate expression and activity of tyrosinase thus promoting melanin synthesis. This 
mechanism is thought to be responsible for the side effects ofPIIP (Scott et al, 2004). 
1.7.2 PROSTANOID (FP) RECEPTOR GENE (PTGFR GENE) 
In human, FP receptor is encoded by prostaglandin receptor F 2a gene (PTGFR), 
mapped to chromosome 1 (p31.1 ). It is a large gene consists of 3 exons spanning 
approximately 1 Okbp of genomic DNA separated by 2 large introns (Appendix A: 
human PTGFR gene). First ex on is about 164b in size, second 870b and largest third 
exon is 1 ,459b in size. Intron 1 starts from position 165 ( -1.3kb) and intron 2 starts 
from position 1035 (6.1kb) (Betz et al, 1999). 
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Exons literally represent the coding regions of a gene and are genetically priority of 
interest and introns conversely represent the non-coding region and biological 
significance of which are still opens to debate. Mutation within such a large gene is 
invariably present and inevitable. Distribution of various SNP in populations and 
subpopulation were known to varies, and to date 164 possible SNPs have been reported 
within the PTGFR gene in world populations. However, there were only 5 SNPs were 
reported within the 3 exons (Figure 1.2; Genbank database search dated Oct 2005). 
Exon 1 
• -- D-IRe!:' EXO>: S~"P 
Exon 2 Exon 3 
-~-
Figure 1.2: Schematic drawing representing the location of the existing Single 
nucleotide polymorphisms (SNP) found within the exon of the PTGFR gene 
(Schematic drawing based on Genbank database search dated Oct 2005) 
Functional significance of these SNPs is still not known to mankind. The potential 
implications of these SNPs to the diseases, and drug response are still waiting to be 
explored. Oguma et al (2004) their research on PTGDR (prostaglandin D receptor 
gene) polymorphism have reported that various haplotype and diplotype of PTGDR 
sequence variants had large functional influence on the patients' susceptibility to 
asthma. 
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There has been extensive research in pharmacogenetic and polymorphism in the past 
few years but very few were done on PTGFR gene. Only research close to this gene 
were done by Sossey et al (200 1) who reported loss of heterozygosity (LOH) of 1 p31 
chromosomal region in nearly 50% of human breast cancer patients. Presence of tumor 
suppressor gene within the gene was suggested. 
The available data on prevalence of SNP was based on Caucasians thus do not 
represent our continent because ethnicity and racial origin in various continents 
displayed different SNP. Thus, exploration of the SNP of PTGFR gene within our 
population needs to start somewhere. It would serve as a comer stone for the relevant 
pharmacogenetic study not only in the field of Ophthalmology but in the other 
disciplines especially the Obstetric and Gynecology field. 
1.8 ADVANCES IN GENETIC LABORATORY STUDIES 
1.8.1 INTRODUCTION 
Currently there has been revolutionary discovery of various laboratory techniques used 
in genetic studies which includes Polymerase Chain Reaction (PCR), Southern Blot 
analysis, Restricted Fragment Length Polymorphism (RFLP), Denaturing High 
Performance Liquid Chromatography (DHPLC) and etc. Selection of most efficient and 
cost effective method are necessary to avoid financial and man power wastage. 
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1.8.2 POLYMERASE CHAIN REACTION (PCR) 
This technique was developed by Kary Mullis whom later received the Nobel Prize in 
chemistry in 1993. It is an efficient technique allows amplification of a selected DNA 
sequence in a genome a millionfold or more, provided the nucleotide sequence of at 
least one short DNA segment on each side of the region of interest is known. 
PCR involve 3 steps: 
1. Step one: Genomic DNA containing the sequence to be amplified is denatured 
by heating. 
2. Step two: The denatured DNA is annealed to an excess of the synthetic 
oligonucleotide primers. 
3. Step three: DNA polymerase (taq polymerase) is used to replicate the DNA 
segment between the sites complementary to the oligonucleotide primers. 
The primer provides the free 3 '-OH required for covalent extension and the denatured 
genomic DNA provides the required template function. The product from one cycle 
would then undergo second cycle which will eventually produce an exponential 
amplification. 
Products of PCR can be detected and confirmed by gel electrophoresis. PCR techniques 
are the prerequisite for product purification in most of the SNP detection techniques 
including dHPLC. 
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1.8.3 DENATURING HIGH PERFORMANCE LIPID CHROMATOGRAPHY 
(dHPLC) 
There are multiple contemporary methods used for the detection of unknown mutations 
which include single-strand conformation polymorphism analysis (SSCP), denaturing 
gradient gel electrophoresis (DOGE), temperature gradient gel electrophoresis (TGGE), 
mismatch cleavage methods (MCM), direct sequencing, oligonucleotide arrays, as well 
as gel electrophoresis and most importantly high-performance liquid chromatography-
based heteroduplex detection (Huber et al, 2000). 
DHPLC identifies mutations and polymorphisms based on observation that 
heteroduplexes will, under partially denaturing conditions, be more likely to denature, 
compared to their homoduplex counterparts (Meldrum et al, 2003). Under partially 
denaturing temperatures, the heteroduplexes elute from the column earlier than the 
homoduplexes because of their reduced melting temperature. DHPLC is a recently 
developed technique popularized by P.J. Oefner. Advantages of dHPLC include high 
sensitivity and specificity, flexibility of fragment size, low labor intensity and operator 
time (O'Donovan et al, 1998). It has emerged the most sensitive method for high 
throughput polymorphisms detection (O'Donovan et al 1998; Sivakumaran et al., 2003; 
Meldrum et al, 2003). 
O'Donovan et al (1998) has reported 100% sensitivity and specificity for fragments less 
than 1 OOObp. Sivakumaran in his review (2003) had found as high as 96% (upto 670bp, 
Jone's et al), 97% (Escary et al), 99.44% (Wagner et al) and 100% (Gross et al) 
sensitivity in 4 studies. The major limitations in various techniques detecting single 
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